Reprogramming Macrophage Phenotype Using a Reactive Oxygen Species-Responsive Liposome Delivery System for Inflammation Microenvironment Remodeling and Osteoarthritis Treatment
- 17 March 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (12) , 17932-17947
Abstract
The progression of osteoarthritis (OA) is closely linked to synovial inflammation caused by an imbalance between M1 and M2 macrophages. To tackle this problem, we developed a liposome responsive to reactive oxygen species (ROS), modified with folic acid ligands to target M1-polarized macrophages, and loaded with the anti-inflammatory agent dimethyl fumarate (DMF). This liposome-based drug delivery system was designed to reprogram macrophage phenotype to remodel the inflammatory microenvironment in the joint cavity and alleviate OA degeneration. The liposome we prepared had a suitable size and negative zeta potential, with uniform size, good stability in aqueous solution, and excellent biocompatibility. Laboratory tests showed that these DMF-filled liposomes notably decreased high levels of ROS in M1-type macrophages and shifted macrophage polarization via the Nrf2/HO-1 pathway, which in turn lessened inflammation in chondrocytes and averted their apoptosis. Additionally, animal studies demonstrated that liposomes containing DMF exhibited notable anti-inflammatory properties, significantly reduced synovial inflammation, safeguarded injured cartilage, reversed changes in subchondral bone, and effectively slowed the progression of osteoarthritis in a mouse model induced by anterior cruciate ligament transection (ACLT). Therefore, ROS-responsive liposomes targeting M1-polarized macrophages represent a promising and valuable approach for OA treatment.Keywords
Funding Information
- Shandong Jiaotong University (YG2022QN074)
- National Natural Science Foundation of China (82172411)
- Shanghai Songjiang District Science and Technology Committee (2023SJKWGG063)
This publication has 52 references indexed in Scilit:
- Reprogramming Macrophage Polarization, Depleting ROS by Astaxanthin and Thioketal‐Containing Polymers Delivering Rapamycin for Osteoarthritis TreatmentAdvanced Science, 2023
- Nanomedicines Reprogram Synovial Macrophages by Scavenging Nitric Oxide and Silencing CA9 in Progressive OsteoarthritisAdvanced Science, 2023
- Dimethyl Fumarate Inhibits Fibroblast Like Synoviocytes-mediated Inflammation and Joint Destruction in Rheumatoid ArthritisInflammation, 2022
- Regulation of Synovial Macrophages Polarization by Mimicking Efferocytosis for Therapy of OsteoarthritisAdvanced Functional Materials, 2022
- What Is Osteoarthritis?JAMA, 2022
- ROS‐Responsive Boronate‐Stabilized Polyphenol–Poloxamer 188 Assembled Dexamethasone Nanodrug for Macrophage Repolarization in Osteoarthritis TreatmentAdvanced Healthcare Materials, 2021
- Dimethyl fumarate prevents ferroptosis to attenuate acute kidney injury by acting on NRF2Clinical and Translational Medicine, 2021
- Diagnosis and Treatment of Hip and Knee OsteoarthritisJAMA, 2021
- Dimethyl fumarate, a two‐edged drug: Current status and future directionsMedicinal Research Reviews, 2019
- Emerging Targets for the Management of Osteoarthritis PainCurrent Osteoporosis Reports, 2016